Natural history of ischemic digital ulcers in systemic sclerosis: Single-center retrospective longitudinal study

Journal of Rheumatology

Volumn 34, Issue 12, 2007, Pages 2423-2430

  Hachulla, Eric ^a   Clerson, Pierre ^b   Launay, David ^a   Lambert, Marc ^a   Morell Dubois, Sandrine ^a   Queyrel, Viviane ^a   Hatron, Pierre Yves ^a  

^a UNIV LILLE   (France)

^b Orgametrie   (France)

Author keywords

Digital ulcer; Natural history; Scleroderma; Systemic sclerosis

Indexed keywords

VASODILATOR AGENT;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DEMOGRAPHY; FEMALE; FINGER AMPUTATION; FOLLOW UP; HISTORY; HUMAN; ISCHEMIC DIGITAL ULCER; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RODNAN SCORE; SMOKING; STATISTICAL PARAMETERS; SYSTEMIC SCLEROSIS;

ADULT; FEMALE; FINGERS; HUMANS; ISCHEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 36849082610     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Masi AT, Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
3. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
4. Belch JJ. Raynaud's phenomenon. Curr Opin Rheumatol 1989;1:490-8.
5. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine Baltimore 1980;59:393-408.
6. O'Hanlon DP. Digital ulcerations in systemic sclerosis. Arthritis Rheum 1984;27:1314.
7. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-7.
8. Pope JE, Bellamy N. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Clin Invest Med 1995;18:1-10.
9. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
10. Della Rossa A, Valentini G, Bombardieri S, et al. European multicenter study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centers. Ann Rheum Dis 2001;60:585-91.
11. Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
12. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine Baltimore 2002;81:139-53.
13. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis of features at diagnosis as predictive factors for survival. Medicine 2002;81:154-67.
14. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002;46:3312-6.
15. Gahhos F, Ariyan S, Frazier WH, Cuono CB. Management of sclerodermal finger ulcers. J Hand Surg [Am] 1984;9:320-7.
16. Winston EL, Pariser KM, Miller KB, Salem DN, Creager MA. Nifedipine as a therapeutic modality for Raynaud's phenomenon. Arthritis Rheum 1983;26:1177-80.
17. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomised study. BMJ 1989;298:561-4.
18. Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. BMJ 1980;281:1031-4.
19. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
20. Torley HI, Madhok R, Capell HA, et al. A double-blind, randomised, multicenter comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
21. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
22. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
23. Meyrick Thomas RH, Rademaker M, Grimes SM, et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 1987;117:237-41.
24. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
25. Seibold JR, Black CM, Denton CP, et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 study [abstract]. ATS 2006; A243.